Acticor: hopes revived in stroke, share price rises

(CercleFinance.com) - Acticor Biotech shares rose sharply on Tuesday on the Paris Bourse, boosted by hopes surrounding the launch of a new Phase II/III trial.


In April, the biopharmaceutical company announced that a Phase III trial in the treatment of acute ischemic stroke had failed to meet its primary and secondary endpoints.

These were to demonstrate a significant reduction in the proportion of patients with severe disability or death 90 days after stroke, and to measure the proportion of patients returning to life without disability.

Since then, data presented at the European Society of Cardiology (ESOC) congress have suggested that a sub-population could potentially benefit from the treatment.

These favorable trends for glenzocimab relate to the so-called 'mRS 0-1' score, i.e. return to normal life, which was the criterion recommended by the FDA.

In a press release issued last night, Acticor confirms that the design of a new Phase 2/3 study evaluating glenzocimab in patients requiring thrombectomy is now 'under development'.

'Given glenzocimab's good safety profile, the launch of a new study does not represent a major challenge from a regulatory standpoint, its completion being conditional above all on dedicated financing', commented analysts at Invest Securities this morning.

At present, the company's financial visibility extends to October 2024, but Acticor confirms that it is still in discussion with potential partners to support future developments', added the brokerage firm.

Following these announcements, Acticor's share price climbed by more than 28% on Tuesday on the Paris Bourse, but was still down by more than 63% since January 1.

Copyright (c) 2024 CercleFinance.com. All rights reserved.